Nearly 80% of people taking calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) for the preventive treatment of migraine reported their migraine as "better" overall since starting their medication, according to a web-based population survey. Close to...
Migraine
Category
Nightly Sleep Disturbances Linked to Daily Risk of Migraines
Investigators from Brigham and Women's Hospital and Beth Israel Deaconess Medical Center have conducted the largest prospective study using objective measures of sleep to date to evaluate the relationship between sleep and migraine headaches. They found that sleep...
Montefiore Helps Lead Investigational Migraine Study Evidencing Promising Results
New York’s Montefiore Headache Center helped conduct a large-scale clinical trial testing Allergan’s ubrogepant with migraine headache patients. The new drug shows promise. Migraine: A Massive Problem Up to 40 million Americans and one billion worldwide suffer form...
NYU Langone Health Leads Digital Therapy App for Migraine Headaches with Positive Results
NYU Langone Health led migraine focused digital therapy study and reports that patients who used the app at least two times a week had fewer migraine episodes throughout the study. Published in Digital Medicine, a journal published by the International Society of...
Digital Migration Therapy: NYU School of Medicine & Irody Inc. Develop New Smartphone Relaxation App
NY School of Medicine, Langone Health researchers teamed up with Irody Inc. to jointly develop an innovative new smartphone relaxation app called RELAXaHEAD for those who suffer from migraines. Migraines A Major Problem Over 36 million suffer from migraines in the...
Albert Einstein College of Medicine-Led Migraine Study Looks Promising
An Albert Einstein College of Medicine-led study shows Rimegepant eliminated or materially decreased migraine symptoms and could provide an alternative to present medications on the market if approved by the Food and Drug Administration (FDA). The Study With over...
Teva’s Fremanezumab (Ajovy) Reported as Cost Effective for Migraine
Ajovy is a drug for migraine prevention. It has been shown to be effective and safe in adult patients suffering from four or more attacks per month. Discovered and developed by Rinat Neuroscience, it came to Pfizer via acquisition in 2006 and thereafter was licensed...
Aarhus University Hospital Study Reports Migraine Complicates Pregnancy
Aahrus University Hospital Denmark conducted a recent study that has revealed that migraine is associated with an increased risk in pregnancy, and is related to hypertension disorders in mothers and newborns. Migraine during pregnancy may lead to significant adverse...
Hallym University Korea Investigators Reveal Psoriasis Increases Risk of Migraine
Researchers from Hallym University and supporting Korean institutions sought to investigate the association of migraines to the autoimmune disorder of psoriasis. Both are inflammatory diseases. However, the investigators noted few prior studies were conducted...
Satsuma Pharmaceuticals Raises $62M to Take Migraine Treatment Through Phase 3 & NDA
Based in prominent biotech hub of South San Francisco, Satsuma Pharmaceuticals (Satsuma) has raised $62 million to finance the Phase III development of its STS101 (dihydroegotamine (DHE) nasal powder) for the acute treatment of migraine. Investors include lead...
Biohaven Announces Acceptance of Investigational New Drug IND Filing for Rimegepant in China
Rimegepant(NYSE: BHVN) is an investigational drug candidate for the treatment of migraine. Originally discovered by Bristol-Myers Squibb, it is currently under development by Biohaven. Based in New Haven, CT. Biohaven is a clinical-stage biopharmaceutical company,...